Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Maltodextrin
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Health Launches Oral Mucositis Product Gelclair in U.S.
Details : Gelclair (maltodextrin) is indicated to alleviate pain by adhering to the mucosal surface of the mouth and treating oral lesions, including oral mucositis/stomatitis.
Product Name : Gelclair
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 16, 2024
Lead Product(s) : Maltodextrin
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Maltodextrin
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Jaguar Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Jaguar Licenses Oral Mucositis Product for U.S. Market in Cancer Care
Details : Gelclair will be commercialized by Jaguar Health in the U.S. to alleviate pain from oral lesions, including mucositis and stomatitis.
Product Name : Gelclair
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Maltodextrin
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Jaguar Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Maltodextrin
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : BioFortis
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effects of Daily Supplementation of Nutriose® on the Fecal Microbiota in Volunteers.
Details : Nutriose is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : Maltodextrin
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : BioFortis
Deal Size : Inapplicable
Deal Type : Inapplicable